文献速递细菌感染、耐药与抗菌药物

头孢洛扎/他唑巴坦单用及联合对多重耐药铜绿假单胞菌的抗菌活性

Antibacterial activity of ceftolozane/tazobactam alone and in combination with other antimicrobial agents against MDR Pseudomonas aeruginosa.
PubMed 文献 · J Antimicrob Chemother · 2018-01-01

该研究通过24小时时间杀菌实验,评估头孢洛扎/他唑巴坦(C/T)单用及与八种抗铜绿假单胞菌药物联用对四株临床多重耐药铜绿假单胞菌(MDR PSA)的活性。结果显示C/T 3g和1.5g q8h的峰浓度对MDR PSA有杀菌作用,黏菌素和磷霉素与C/T联用(双联或三联)呈现协同作用。

要点

  • C/T 3g和1.5g q8h峰浓度对MDR PSA有杀菌活性。
  • 黏菌素和磷霉素与C/T联用显示协同作用。
  • C/T联合方案可能为MDR PSA治疗提供新选择。

核心结论

  • C/T 3g和1.5g q8h峰浓度对四株临床MDR PSA分离株有杀菌作用。
  • 黏菌素和磷霉素与C/T联用(双联和三联方案)表现出协同作用。

研究设计与样本

  • 采用24小时时间杀菌实验(一式两份),评估C/T单用及联合八种抗铜绿假单胞菌药物对四株临床MDR PSA分离株的活性。
  • C/T浓度模拟人3g q8h的游离峰浓度(120/25.2 mg/L)及1.5g q8h的峰浓度(60/12.6 mg/L)和谷浓度(7.5/1.6 mg/L)。

主要发现

  • C/T 120、60和7.5 mg/L单用对MDR PSA的杀菌效果被测试。
  • C/T 7.5 mg/L与头孢吡肟、环丙沙星、黏菌素、氨曲南、美罗培南、哌拉西林/他唑巴坦、磷霉素和丁胺卡那的临床剂量游离峰谷浓度联用的活性被评估。
  • 黏菌素和磷霉素与C/T联用显示协同作用。

临床怎么用

  • 对于MDR PSA感染,可考虑C/T与黏菌素或磷霉素联合治疗。
  • C/T 3g和1.5g q8h的峰浓度可达到对MDR PSA的杀菌暴露。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Broad-spectrum antimicrobial resistance in Pseudomonas aeruginosa (PSA) isolates is a growing concern as our therapeutic options have become significantly limited. Although ceftolozane/tazobactam (C/T) has been shown to be highly active against MDR PSA pathogens, combination regimens are often employed in real-world settings. To assist the clinical decision-making process regarding the selection of combination antibiotics and dosages for this pathogen, we performed time-kill studies assessing clinical free peak and trough C/T concentrations alone and in combination with eight anti-pseudomonal agents against four clinical MDR PSA isolates. METHODS: Time-kill analyses were performed over 24 h in duplicate using C/T concentrations reflective of the free peak concentrations of a 3 g dose every 8 h (q8h; 120/25.2 mg/L) and the peak and trough of a 1.5 g q8h dose (60/12.6 and 7.5/1.6 mg/L) in humans. The activity of C/T 120, 60 and 7.5 mg/L alone and C/T 7.5 mg/L in combination with free peak and trough concentrations of clinical doses for cefepime, ciprofloxacin, colistin, aztreonam, meropenem, piperacillin/tazobactam, fosfomycin and amikacin was tested for all isolates. RESULTS: C/T 3 and 1.5 g q8h peak concentrations demonstrated killing against the MDR PSA. Colistin and fosfomycin were synergistic with C/T as dual therapy and triple therapy regimens. CONCLUSIONS: As a result of escalating resistance, PSA is an increasingly challenging pathogen in the clinical setting. Our findings aid in the identification of novel treatment options using achievable drug exposures for the treatment of MDR PSA.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Monogue ML, Nicolau DP. Antibacterial activity of ceftolozane/tazobactam alone and in combination with other antimicrobial agents against MDR Pseudomonas aeruginosa. J Antimicrob Chemother. 2018. PMID: 29272436. doi:10.1093/jac/dkx483

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。